Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / Author: Graham Hand

Graham Hand

Cuffelinks Firstlinks Edition 307

How good are franking credits? Interview with Charles Dalziell, SMSFs need friends, Don Stammer, IPOs not worth it, future of retirement, politics.

Charles Dalziell on life as a contrarian investor

How does a style that relies on investing in stocks the market dislikes sustain itself over time, when inevitably investors go through difficult markets until the value is realised? It’s not an easy way to run a fund manager.

Cuffelinks Firstlinks Edition 306

Election countdown, 7 ways to fix franking loss, more tax avoidance, contributions tax, CGT, investing rules of thumb, behaviour, AI ethics.

7 strategies to manage a loss of franking

Much has been written about Labor's franking policy, so we bring together a range of possible strategies. It's likely that even if implemented, it will not be in its current guise, so anyone affected should wait before taking action.

Cuffelinks Firstlinks Edition 305

New Interview Series, Lynch & Buffett lessons, Montgomery on Uber, Microsoft, Joe Magyer, Noel on 10% rule, bonds & hybrids for franking.

Joe Magyer on pricing power, customer loyalty and the network effect

How does a small company fund manager identify customer loyalty, pricing power and network effects in a niche business trading at a high valuation, especially when so much value is in the future.

Latest Updates

Economy

Get set for a bumpy 2026

At this time last year, I forecast that 2025 would likely be a positive year given strong economic prospects and disinflation. The outlook for this year is less clear cut and here is what investors should do.

Investment strategies

History says US market outperformance versus Australia will turn

Much has been made of how US markets, especially the NASDAQ, have significantly outperformed the ASX over the past two decades. History suggests the pendulum will swing back once again in Australia's favour.

Investment strategies

Announcing the X-Factor for 2025

What is the X-Factor - the largely unexpected influence that wasn’t thought about when the year began but came from left field to have powerful effects on investment returns - for 2025? It's time to select the winner.

Economy

The illusion of progress

What is progress? Is it GDP growth? Increasing wealth? New and improving technology? This argues that our measure of progress has become warped, and we're heading backwards rather than forwards.

Strategy

Our favourite summer reads

Summer is a great time to catch up on a good book. Here is a list of books on leadership, investing, and well-being for those looking to learn, reflect, and gain inspiration over the holiday season.

Sponsors

Alliances

© 2026 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.